Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297611 | 1.00 | SRC (0.52) | SRCTNFSF11SLC2A1ALKPARP1 | |
| SCHEMBL1998529 | 0.94 | SLC2A1 (0.54) | SRCTNFSF11SLC2A1PARP1CHEK1 | |
| SCHEMBL4018984 | 0.91 | SLC2A1 (0.46) | SRCTNFSF11SLC2A1ALKPARP1 | |
| SCHEMBL3725738 | 0.91 | SLC2A1 (0.46) | SRCTNFSF11SLC2A1ALKPARP1 | |
| SCHEMBL6253346 | 0.89 | SRC (0.52) | SRCSLC2A1ALKPARP1CHEK1 | |
| SCHEMBL8917 | 0.88 | SRC (0.63) | SRCSLC2A1PARP1CHEK1PIM1 | |
| SCHEMBL3231833 | 0.86 | SLC2A1 (0.47) | SRCSLC2A1PARP1CHEK1PIM1 | |
| SCHEMBL17967511 | 0.85 | SRC (0.49) | SRCSLC2A1ALKPARP1CHEK1 | |
| SCHEMBL27576840 | 0.84 | SLC2A1 (0.50) | SRCSLC2A1PARP1CHEK1PIM1 | |
| SCHEMBL13090425 | 0.84 | SLC2A1 (0.50) | SLC2A1PARP1CHEK1PIM1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721551-B | Preparation method of 3, 4-dihydro-7-methoxy-4-oxoquinazolin-6-ol acetate | 上海北卡医药技术有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | claimed |
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | claimed |
| CN-112730702-A | Method for determining related substances of 6-acetoxyl-7-methoxy-3H-quinazoline-4-one | 南京百泽医药科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20170114027-A1 | NOVEL QUINAZOLINE DERIVATIVE LU1501 AND PREPARING METHOD AND APPLICATION THEREOF | Nanjing General Hospital of Nanjing Military Region of PLA (CN) | 2017-04-27 | — | — | US | claimed |
| US-9624179-B1 | Quinazoline derivative Lu1501 and preparing method and application thereof | Nanjing General Hospital of Nanjing Military Region of PLA (CN) | 2017-04-18 | — | — | US | claimed |
| US-7803559-B1 | Protein aggregation regulators | THE REGENTS OF THE UNIVERSITY OF CA (US) | 2010-09-28 | — | — | US | claimed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-120040358-A | Preparation method and application of quinazoline derivative containing chalcone | 沈阳工业大学 | 2025-05-27 | — | — | CN | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-114516862-B | Quinazoline derivative and preparation method and application thereof | 河北康泰药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117285518-A | Quinazoline derivative containing benzofuran structure and application thereof | 华侨大学 | 2023-12-26 | — | — | CN | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997038994-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-10-23 | — | — | WO | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114027-A1 | NOVEL QUINAZOLINE DERIVATIVE LU1501 AND PREPARING METHOD AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, SKP1 | SRC 4568/4885TNFSF11 4885/4885SLC2A1 2900/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | SRC 474/4885TNFSF11 4801/4885SLC2A1 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.